MYC and colorectal carcinoma: Transcriptomic analysis identified four consensual molecular subtypes (CMS) of CRC: CMS1—microsatellite instability (MSI-H)/immunogenic tumors, accounting for 14% of all CRC cases and hypermutated with strong immune activation; CMS2—canonical tumors (37% of CRC cases), epithelial and exhibiting MYC and WNT signaling pathway activation; CMS3—metabolic (13% of CRC cases), epithelial, and displaying evident metabolic dysregulation; and CMS4—mesenchymal (23% of all CRC) featuring stromal invasion, transforming growth factor-beta activation, and angiogenesis [1].